MedTrace Logo

Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma

NCT00897546 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1716

Last updated 2017-05-19

No results posted yet for this study

Summary

RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer, and may help doctors learn how well patients will respond to treatment.

PURPOSE: This laboratory study is looking at biomarkers to predict the response to interferon therapy in patients with melanoma.

Conditions

  • Melanoma (Skin)

Interventions

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • ECOG-ACRIN Cancer Research Group

    lead NETWORK

Principal Investigators

  • Elieser Gorelik, MD, PhD · University of Pittsburgh

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-01
Primary Completion
2008-07-01
Completion
2008-07-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00897546 on ClinicalTrials.gov